# A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

> **NCT04202159** · — · COMPLETED · sponsor: **Eisai GmbH** · enrollment: 187 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Perampanel
- **DRUG:** Perampanel

## Key facts

- **NCT ID:** NCT04202159
- **Lead sponsor:** Eisai GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-21
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04202159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04202159, "A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04202159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*